Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML.

Antimicrobial agents and chemotherapy·2026

Same author

Rising Antifungal Resistance in Candidozyma auris: Signals, Gaps, and the Path Forward.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Global Review on <i>Naegleria fowleri</i> Cases: Contemporary Epidemiology, Diagnosis, Treatment and Outcomes.

Infectious disease reports·2026

Same author

Epidemiology and Clinical Features of Cryptococcosis Among Individuals Without HIV Infection: An Observational International Multicenter Study (MSG-11).

Open forum infectious diseases·2026

Same author

CAMEO-a cross-sectional survey study on candidemia management in Germany.

Medical mycology·2026

Same author

Profiling medical mycologists: Results from a global survey of the ESCMID Fungal Infection Study Group (EFISG).

Medical mycology·2026

Search research articles

Related Experiment Video

Updated: May 11, 2026

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

Seroprevalence of SARS-CoV-2 antibodies in patients with hematological and oncological diseases in early 2024.

Louise M Cremer^1,2,3, Jannik Stemler^4,5,6, Rosanne Sprute^4,5,6

¹University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany. louise.cremer@uk-koeln.de.

|March 28, 2025

Summary

This summary is machine-generated.

COVID-19 antibody levels vary significantly in immunocompromised patients with cancer. Antibody levels depend on specific hematological/oncological diseases and treatment status, indicating a need for tailored booster vaccinations.

Keywords:

Immunocompromised patients COVID-19 Communicable disease SARS-CoV-2 Seroprevalence Vaccination

More Related Videos

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

COVID-19 Seroprevalence Test for IgG Antibody Levels Among Healthy Donors Across Different Pandemic Phases in Jeddah

COVID-19 Seroprevalence Test for IgG Antibody Levels Among Healthy Donors Across Different Pandemic Phases in Jeddah

Published on: June 24, 2025

Related Experiment Videos

Last Updated: May 11, 2026

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

COVID-19 Seroprevalence Test for IgG Antibody Levels Among Healthy Donors Across Different Pandemic Phases in Jeddah

COVID-19 Seroprevalence Test for IgG Antibody Levels Among Healthy Donors Across Different Pandemic Phases in Jeddah

Published on: June 24, 2025

Area of Science:

Immunology
Oncology
Virology

Background:

COVID-19 poses a significant risk to immunocompromised individuals.
Assessing SARS-CoV-2 antibody levels is crucial for evaluating vaccine efficacy in high-risk patients.
Understanding immune response variations informs strategies for managing COVID-19 in vulnerable populations.

Purpose of the Study:

To determine the status of circulating SARS-CoV-2 antibodies in immunocompromised patients after winter.
To analyze the need for booster vaccinations in patients with hematological and oncological diseases.
To investigate variations in anti-spike IgG levels based on disease type, treatment, and demographics.

Main Methods:

Measured anti-spike IgG levels in 46 hospitalized patients with hematological/oncological diseases (Dec 2023 - Feb 2024).
Collected demographic data, underlying diseases, antineoplastic treatment details, and SARS-CoV-2 test history.
Compared antibody levels across patient subgroups.

Main Results:

Significant variations in SARS-CoV-2 anti-spike IgG levels were observed across different hematological and oncological diseases.
Highest antibody levels were in patients with diffuse large cell B-cell lymphoma (DLBCL) and acute leukemia initiating or not yet on treatment.
Lowest levels were in patients with DLBCL, acute leukemia, and multiple myeloma who had received prior treatment. Antibody titers were higher in females and those aged 41-50, lowest in 61-70 age group.

Conclusions:

Broad variations in SARS-CoV-2 anti-spike IgG levels exist in patients with hematological/oncological diseases.
Cancer biology, immune dysfunction, and treatment significantly interfere with immune responses.
Regular booster vaccinations are emphasized for this high-risk patient group.